Andrew Cunningham, PhD, is the Vice President and General Manager of XenoSTART, START’s preclinical business unit. He brings more than three decades of industry experience in clinical research from drug discovery, translational science, Phase I-III and post-approval clinical practice.

In support of many early and late phase global trials, Andrew has a record of delivering best-in-class scientific and operational performance to deliver customer needs across multiple therapeutic areas. Prior to joining XenoSTART, Andrew held multiple operational and scientific leadership roles across the clinical research industry and managed bioanalytical and clinical pathology lab networks within global CROs, pediatric and adult healthcare systems.

Andrew holds a bachelors in Biochemistry from the University of Strathclyde and a PhD in leukemia pathology from the University of Edinburgh in the UK.